PortalPublikationenIbrutinib for bridging to allogeneic hematopoietic cell tran...

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Standard

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. / Dreger, Peter; Michallet, Mauricette; Bosman, Paul; Dietrich, Sascha; Sobh, Mohamad; Boumendil, Ariane; Nagler, Arnon; Scheid, Christof; Cornelissen, Jan; Niederwieser, Dietger; Müller, Lutz; Vandenberghe, Elizabeth; Scortechini, Ilaria; Schoemans, Helene; Andersen, Niels S; Finke, Jürgen; Russo, Domenico; Ljungman, Per; Passweg, Jakob; van Gelder, Michel; Durakovic, Nadira; Labussiere-Wallet, Helene; Berg, Tobias; Wulf, Gerald; Bethge, Wolfgang; Bunjes, Donald; Stilgenbauer, Stefan; Canepari, Maria Elisa; Schaap, Michel; Fox, Christopher P; Kröger, Nicolaus; Montoto, Silvia; Schetelig, Johannes.

in: BONE MARROW TRANSPL, Jahrgang 54, Nr. 1, 01.2019, S. 44-52.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Dreger, P, Michallet, M, Bosman, P, Dietrich, S, Sobh, M, Boumendil, A, Nagler, A, Scheid, C, Cornelissen, J, Niederwieser, D, Müller, L, Vandenberghe, E, Scortechini, I, Schoemans, H, Andersen, NS, Finke, J, Russo, D, Ljungman, P, Passweg, J, van Gelder, M, Durakovic, N, Labussiere-Wallet, H, Berg, T, Wulf, G, Bethge, W, Bunjes, D, Stilgenbauer, S, Canepari, ME, Schaap, M, Fox, CP, Kröger, N, Montoto, S & Schetelig, J 2019, 'Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties', BONE MARROW TRANSPL, Jg. 54, Nr. 1, S. 44-52. https://doi.org/10.1038/s41409-018-0207-4

APA

Dreger, P., Michallet, M., Bosman, P., Dietrich, S., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Niederwieser, D., Müller, L., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N. S., Finke, J., Russo, D., Ljungman, P., Passweg, J., ... Schetelig, J. (2019). Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. BONE MARROW TRANSPL, 54(1), 44-52. https://doi.org/10.1038/s41409-018-0207-4

Vancouver

Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A et al. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. BONE MARROW TRANSPL. 2019 Jan;54(1):44-52. https://doi.org/10.1038/s41409-018-0207-4

Bibtex

@article{a748b3121d9c484babfbf8a184305984,
title = "Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties",
abstract = "The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients. The cumulative incidence of chronic GVHD was 54% 1 year after transplant. In the CLL group, 12-month non-relapse mortality, relapse incidence (RI), progression-free survival (PFS), and overall survival (OS) were 10, 30, 60, and 72%, respectively, and in the MCL group 5, 19, 76, and 86%, respectively. Pre-transplant ibrutinib failure and poor performance status predicted inferior RI, PFS and OS in the CLL group. In conclusion, ibrutinib does not affect the safety of a subsequent alloHCT. While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrutinib with alloHCT seems to be a promising option.",
keywords = "Journal Article",
author = "Peter Dreger and Mauricette Michallet and Paul Bosman and Sascha Dietrich and Mohamad Sobh and Ariane Boumendil and Arnon Nagler and Christof Scheid and Jan Cornelissen and Dietger Niederwieser and Lutz M{\"u}ller and Elizabeth Vandenberghe and Ilaria Scortechini and Helene Schoemans and Andersen, {Niels S} and J{\"u}rgen Finke and Domenico Russo and Per Ljungman and Jakob Passweg and {van Gelder}, Michel and Nadira Durakovic and Helene Labussiere-Wallet and Tobias Berg and Gerald Wulf and Wolfgang Bethge and Donald Bunjes and Stefan Stilgenbauer and Canepari, {Maria Elisa} and Michel Schaap and Fox, {Christopher P} and Nicolaus Kr{\"o}ger and Silvia Montoto and Johannes Schetelig",
year = "2019",
month = jan,
doi = "10.1038/s41409-018-0207-4",
language = "English",
volume = "54",
pages = "44--52",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

AU - Dreger, Peter

AU - Michallet, Mauricette

AU - Bosman, Paul

AU - Dietrich, Sascha

AU - Sobh, Mohamad

AU - Boumendil, Ariane

AU - Nagler, Arnon

AU - Scheid, Christof

AU - Cornelissen, Jan

AU - Niederwieser, Dietger

AU - Müller, Lutz

AU - Vandenberghe, Elizabeth

AU - Scortechini, Ilaria

AU - Schoemans, Helene

AU - Andersen, Niels S

AU - Finke, Jürgen

AU - Russo, Domenico

AU - Ljungman, Per

AU - Passweg, Jakob

AU - van Gelder, Michel

AU - Durakovic, Nadira

AU - Labussiere-Wallet, Helene

AU - Berg, Tobias

AU - Wulf, Gerald

AU - Bethge, Wolfgang

AU - Bunjes, Donald

AU - Stilgenbauer, Stefan

AU - Canepari, Maria Elisa

AU - Schaap, Michel

AU - Fox, Christopher P

AU - Kröger, Nicolaus

AU - Montoto, Silvia

AU - Schetelig, Johannes

PY - 2019/1

Y1 - 2019/1

N2 - The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients. The cumulative incidence of chronic GVHD was 54% 1 year after transplant. In the CLL group, 12-month non-relapse mortality, relapse incidence (RI), progression-free survival (PFS), and overall survival (OS) were 10, 30, 60, and 72%, respectively, and in the MCL group 5, 19, 76, and 86%, respectively. Pre-transplant ibrutinib failure and poor performance status predicted inferior RI, PFS and OS in the CLL group. In conclusion, ibrutinib does not affect the safety of a subsequent alloHCT. While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrutinib with alloHCT seems to be a promising option.

AB - The aim of this retrospective study was to investigate the safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients pre-treated with ibrutinib. Eligible were patients aged >18 years allotransplanted for chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL) after prior exposure to ibrutinib who were registered with the EBMT registry. Seventy patients (CLL 48, MCL 22) were included. At the time of alloHCT, 73% of the patients were ibrutinib responsive. All patients except one engrafted, and acute GVHD grade 2-4 (3-4) was observed in 49% (12%) of 68 evaluable patients. The cumulative incidence of chronic GVHD was 54% 1 year after transplant. In the CLL group, 12-month non-relapse mortality, relapse incidence (RI), progression-free survival (PFS), and overall survival (OS) were 10, 30, 60, and 72%, respectively, and in the MCL group 5, 19, 76, and 86%, respectively. Pre-transplant ibrutinib failure and poor performance status predicted inferior RI, PFS and OS in the CLL group. In conclusion, ibrutinib does not affect the safety of a subsequent alloHCT. While the relatively high post-transplant relapse risk in ibrutinib-exposed patients with CLL deserves further study, in patients with MCL consolidating disease responses to ibrutinib with alloHCT seems to be a promising option.

KW - Journal Article

U2 - 10.1038/s41409-018-0207-4

DO - 10.1038/s41409-018-0207-4

M3 - SCORING: Journal article

C2 - 29728701

VL - 54

SP - 44

EP - 52

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 1

ER -